HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pain attenuating actions of vincristinet-preconditioning in chemotherapeutic agent-induced neuropathic pain: key involvement of T-type calcium channels.

Abstract
Preconditioning is a well-documented strategy that induces hepatic protection, renal protection, cardioprotection, and neuroprotection but its mechanism still remains to be elucidated. Hence, the present study investigated the protective mechanism underlying pain attenuating effects of vincristine-preconditioning in chemotherapeutic agent-induced neuropathic pain. Neuropathic pain was induced by administration of vincristine (50 µg/kg, i.p.) for 10 days in rats. Vincristine-preconditioning was induced by administration of vincristine (2, 5, and 10 µg/kg, i.p) for 5 days before administration of pain-inducing dose of vincristine (50 µg/kg, i.p.). Vincristine-preconditioning (10 µg/kg, i.p) for 5 days significantly reduced vincristine (50 µg/kg, i.p.) induced pain-related behaviors including paw cold allodynia, mechanical hyperalgesia, and heat hyperalgesia. However, vincristine (2 and 5 µg/kg, i.p) did not significantly ameliorate the vincristine (50 µg/kg, i.p.) induced neuropathic pain in rats. Furthermore, to explore the involvement of calcium channels in pain attenuating mechanism of vincristine-preconditioning, T-type calcium channel blocker, ethosuximide (100 and 200 mg/kg, i.p.) and L-type calcium channel blocker, amlodipine (5 and 10 mg/kg, i.p.) were used. Pretreatment with T-type calcium channel blocker, ethosuximide significantly abolished vincristine-preconditioning-induced protective effect. However, pretreatment with L-type calcium channel blocker, amlodipine did not alter vincristine-preconditioning-induced pain-related behaviors. This indicates that vincristine-preconditioning has protective effect on pain-related parameters due to opening of calcium channels, particularly T-type calcium channels that lead to entry of small magnitude of intracellular calcium through these channels and prevent the deleterious effects of high-dose vincristine.
AuthorsJasmine Sharma, Leonid N Maslov, Nirmal Singh, Amteshwar Singh Jaggi
JournalFundamental & clinical pharmacology (Fundam Clin Pharmacol) Vol. 34 Issue 3 Pg. 336-344 (Jun 2020) ISSN: 1472-8206 [Electronic] England
PMID31797451 (Publication Type: Journal Article)
Copyright© 2019 Société Française de Pharmacologie et de Thérapeutique.
Chemical References
  • Antineoplastic Agents
  • Calcium Channel Blockers
  • Calcium Channels, T-Type
  • Amlodipine
  • Vincristine
  • Ethosuximide
  • Calcium
Topics
  • Amlodipine (pharmacology)
  • Animals
  • Antineoplastic Agents (adverse effects)
  • Calcium (metabolism)
  • Calcium Channel Blockers (pharmacology)
  • Calcium Channels, T-Type (metabolism)
  • Ethosuximide (pharmacokinetics)
  • Female
  • Hyperalgesia (chemically induced, drug therapy, metabolism)
  • Male
  • Neuralgia (chemically induced, drug therapy, metabolism)
  • Rats
  • Rats, Wistar
  • Vincristine (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: